WA biotech duo takes aim at diabetes beyond Ozempic A WA biotech duo, ProGenis and Syngenis Laboratories, is developing RNA-based therapies at the next frontier in diabetes medicine, while building Australia’s first RNA facility.
Original (en)
A WA biotech duo, ProGenis and Syngenis Laboratories, is developing RNA-based therapies at the next frontier in diabetes medicine, while building Australia’s first RNA facility.
Published
May 7, 2026, 08:51 AM UTC
6d ago
Significance
Novo Nordisk CEO says the drugmaker is more active than ever in seeking out deals Novo Nordisk CEO Mike Doustdar says the Ozempic and Wegovy maker is looking for deals more than ever before.
WA biotech duo takes aim at diabetes beyond Ozempic A WA biotech duo, ProGenis and Syngenis Laboratories, is developing RNA-based therapies at the next frontier in diabetes medicine, while building Australia’s first RNA facility.
WA biotech duo takes aim at diabetes beyond Ozempic A WA biotech duo, ProGenis and Syngenis Laboratories, is developing RNA-based therapies at the next frontier in diabetes medicine, while building Australia’s first RNA facility.
6049036d…openwatch.io →